Research Article
In Situ Thrombosis of Small Pulmonary Arteries in Pulmonary Hypertension Developing after Chemotherapy for Malignancy
Table 2
Clinical findings of patients with in situ thrombosis.
| | Case | Clinical symptoms | Computed tomography | Echocardiography | PAG | Clinical outcome |
| | 1 | DOE | Ground-glass opacity
Diffuse patchy nodular interstitial opacity | Normal | Tapering vascular shadow of both upper lungs, mPAP = 30 mmHg | Oxygen therapyimproved | | 2 | Polypnoea, hypoxemia | Ground-glass opacity
Pleural effusion | mPAP = 70–75, 55 mmHg (under NO),
RVH | — | Diureticssevere PHNO, PDE5i, PGI2anticoagulantsimproved | | 3 | DOE, hypoxemia, polypnoea, | Ground-glass opacity | mPAP = 40–50 mmHg | — | NO, PDE5i, PGI2anticoagulants, antithrombotic drugsimproved | | 4 | Hypoxemia, sudden chest-abdominal pain | — | mPAP = 50–55 mmHg | — | Oxygensudden cardiopulmonary arrest (death) |
|
|
DOE = dyspnea on exertion; mPAP = mean pulmonary artery pressure; PAG = pulmonary angiography; PDE5i = cGMP-specific phosphodiesterase type 5 inhibitor; PGI2 = prostaglandin I2; PH = pulmonary hypertension; RVH = right ventricular enlargement.
|
